Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease

• DOI: 10.1097/wnf.0b013e3181ebb285
• Publication Date: 2010-07-08T08:21:11Z
• Authors: Anders Lundin; Espen Dietrichs; Sara Haghighi; Marie-Louise Göller; Arvid Heiberg; Ghada Loutfi; Håkan Widner; Klas Wiktorin; Leif Wiklund; Anders Svenningsson; Clas Sonesson; Nicholas Waters; Susanna Waters; Joakim Tedroff
• Keywords: Verbal fluency test; Clinical Global Impression

Objectives: To evaluate the efficacy and safety of dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD). Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, HD received (50 mg/d, n = 28) or placebo (n 30). The primary outcome measure was change from baseline weighted cognitive score, assessed by tests (Symbol Digit Modalities, verbal fluency, Stroop tests). Secondary measures included changes Unified Disease Rating Scale, Hospital Anxiety Depression Leeds Sleep Evaluation Questionnaire, Reitan Trail-Making Test A, Clinical Global Impression Change. Safety assessments were also performed. Results: There no significant difference between score. However, secondary such as affective symptoms showed trends toward improvement, there improvement voluntary motor compared (P < 0.05). Pridopidine well tolerated, profile similar to placebo. Conclusions: shows promise treatment for some HD. this small-scale study, most notable effect symptoms. Larger, longer-term trials are warranted.